Skip to content
sellWeak

Laura Brege sold $315k of ACAD

director at ACADIA PHARMACEUTICALS INC. 14,446 shares at an average of $21.78, traded Jun 4, 2025, filed Jun 5, 2025.

Warning score
39
Value
$315k
14,446 shares
Holdings after
15,095
-49% from before
From 52-week low
+54%
low $14.10, close $21.77
From 52-week high
-2%
high $22.29, as of Jun 4, 2025

Score components

  • Role
    Director
    +15
  • Trade size
    $315k at market
    +14
  • Share of holdings sold
    Sold 49% of holdings
    +10
  • Cluster
    No other insider selling within 14 days
    0

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

ACADOct 9, 2026 · close 19.78
Since filing Jun 5, 2025: -7.3%SPY +33.5% · excess -40.8%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001415889-25-015832, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Jun 4, 2025SOpen-market sale
Common Stock
-14,446$21.78$315k15,095Jun 5, 2025

Related signals

Other insiders at ACADIA PHARMACEUTICALS INC and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
17Weak
ACADsell 210b5-1
ACADIA PHARMACEUTICALS INC
Mark C. Schneyer
EVP, CHIEF FINANCIAL OFFICER
$50k
2,000 shares
-3%
17Weak
ACADsell 210b5-1
ACADIA PHARMACEUTICALS INC
James Kihara
PRINCIPAL ACCOUNTING OFFICER
$90k
4,000 shares
-16%
2Weak
ACADsell 210b5-1
ACADIA PHARMACEUTICALS INC
Mark C. Schneyer
EVP, CHIEF FINANCIAL OFFICER
$51k
3,498 shares
-5%
0Weak
ACADsell 210b5-1
ACADIA PHARMACEUTICALS INC
James Kihara
PRINCIPAL ACCOUNTING OFFICER
$19k
1,327 shares
-5%
0Weak
ACADsell 210b5-1
ACADIA PHARMACEUTICALS INC
James Kihara
PRINCIPAL ACCOUNTING OFFICER
$15k
1,028 shares
-4%
1Weak
ACADsell 210b5-1
ACADIA PHARMACEUTICALS INC
Mark C. Schneyer
EVP, CHIEF FINANCIAL OFFICER
$40k
2,708 shares
-4%
2Weak
ACADsell 210b5-1
ACADIA PHARMACEUTICALS INC
Mark C. Schneyer
EVP, CHIEF FINANCIAL OFFICER
$54k
3,171 shares
-5%
0Weak
ACADsell 210b5-1
ACADIA PHARMACEUTICALS INC
James Kihara
PRINCIPAL ACCOUNTING OFFICER
$19k
1,095 shares
-5%
44Moderate
ACADsell 3
ACADIA PHARMACEUTICALS INC
Elizabeth A. Garofalo
director
$90k
4,919 shares
-22%
2Weak
ACADsell 310b5-1
ACADIA PHARMACEUTICALS INC
Mark C. Schneyer
EVP, CHIEF FINANCIAL OFFICER
$15k
773 shares
-1%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Laura Brege sold $315k of ACAD | InsiderTell